Market Spotlight: Uterine Cancer
Market Spotlight: Uterine Cancer
$1,318.00
This Market Spotlight report covers the uterine cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the uterine cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were 385,200 incident cases of uterine cancer in females worldwide, and expects that number to increase to 404,300 incident cases by 2028.
- In the same year, there were an estimated 1.3 million five-year prevalent cases of uterine cancer worldwide, which is expected to increase slightly to 1.4 million cases by 2028.
- Merck & Co’s Keytruda and Eisai’s Lenvima are the only FDA-approved drugs for uterine cancer. These drugs are administered via the intravenous and oral routes, respectively.
- The majority of industry-sponsored drugs in active clinical development for uterine cancer are in Phase II, with only one drug in the NDA/BLA stage.
- Therapies in active clinical development for uterine cancer focus on a wide variety of targets. These drugs are administered via the oral and intravenous routes.
- High-impact upcoming events for the drugs in the uterine cancer space comprise topline Phase II trial results for XBIO-101, and an estimated PDUFA date for dostarlimab.
- The overall likelihood of approval of a Phase I solid tumors asset is 5.7%, and the average probability a drug advances from Phase III is 41.9%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
- There have been nine licensing and asset acquisition deals involving endometrial cancer drugs during 2015–20. The $1,119m exclusive licensing agreement signed in 2016 between Exelixis and Ipsen, pursuant to which Ipsen will have exclusive commercialization rights for current and potential future cabozantinib indications outside the US, Canada and Japan, was the largest deal.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for uterine neoplasms have been in the early and mid-phases of development, with 95% of trials in Phase I–II, and only 5% in Phase III–IV.
- The US has a substantial lead in the number of uterine neoplasms clinical trials globally, while France, Germany, Spain, and the UK lead the major European markets.
- Sanofi has the highest number of completed clinical trials for uterine neoplasms, with five trials.
- AstraZeneca leads the industry sponsors with the highest overall number of clinical trials for uterine neoplasms
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Surgery
9 Radiation therapy
9 Chemotherapy
10 Hormone therapy
10 Palliative care
11 EPIDEMIOLOGY
15 MARKETED DRUGS
17 PIPELINE DRUGS
23 RECENT EVENTS AND ANALYST OPINION
23 MGA012 for Uterine Cancer (July 2, 2019)
23 Sacituzumab Govitecan for Uterine Cancer (April 29, 2019)
24 TAK-117 for Uterine Cancer (March 20, 2019)
25 Dostarlimab for Uterine Cancer (March 19, 2019)
27 DKN-01 for Uterine Cancer (March 18, 2019)
28 Dostarlimab for Uterine Cancer (October 20, 2018)
31 KEY UPCOMING EVENTS
32 KEY REGULATORY EVENTS
32 Dostarlimab Submitted For (Relatively) Broad Endometrial Cancer Indication
32 FDA Issues Pair Of RTOR Approvals To Keytruda/Lenvima Combo, Erleada
32 Tesaro’s On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer
33 PROBABILITY OF SUCCESS
34 LICENSING AND ASSET ACQUISITION DEALS
34 Deals Shaping The Medical Industry, August 2019
35 PARENT PATENTS
36 REVENUE OPPORTUNITY
37 CLINICAL TRIAL LANDSCAPE
38 Sponsors by status
39 Sponsors by phase
41 BIBLIOGRAPHY
41 Prescription Information
42 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of uterine cancer, 2019–28
17 Figure 2: Overview of pipeline drugs for uterine cancer in the US
17 Figure 3: Pipeline drugs for uterine cancer, by company
18 Figure 4: Pipeline drugs for uterine cancer, by drug type
18 Figure 5: Pipeline drugs for uterine cancer, by classification
27 Figure 6: Dostarlimab for Uterine Cancer (March 19, 2019): Phase I/II – GARNET
28 Figure 7: DKN-01 for Uterine Cancer (March 18, 2019): Phase II – Gynecologic Malignancies (P204)
30 Figure 8: Dostarlimab for Uterine Cancer (October 20, 2018): Phase I/II – GARNET
31 Figure 9: Key upcoming events in uterine cancer
33 Figure 10: Probability of success in the uterine cancer pipeline
34 Figure 11: Licensing and asset acquisition deals in uterine cancer, 2015–20
35 Figure 12: Parent patents in uterine cancer
37 Figure 13: Clinical trials in uterine cancer
37 Figure 14: Top 10 drugs for clinical trials in uterine cancer
38 Figure 15: Top 10 companies for clinical trials in uterine cancer
38 Figure 16: Trial locations in uterine cancer
39 Figure 17: Uterine cancer trials status
40 Figure 18: Uterine cancer trials sponsors by phase
LIST OF TABLES
12 Table 1: Incident cases of uterine cancer, 2019–28
14 Table 2: Five-year prevalent cases of uterine cancer, 2019–28
16 Table 3: Marketed drugs for uterine cancer
19 Table 4: Pipeline drugs for uterine cancer in the US
23 Table 5: MGA012 for Uterine Cancer (July 2, 2019)
24 Table 6: Sacituzumab Govitecan for Uterine Cancer (April 29, 2019)
25 Table 7: TAK-117 for Uterine Cancer (March 20, 2019)
26 Table 8: Dostarlimab for Uterine Cancer (March 19, 2019)
27 Table 9: DKN-01 for Uterine Cancer (March 18, 2019)
29 Table 10: Dostarlimab for Uterine Cancer (October 20, 2018)
36 Table 11: Historical global sales, by drug ($m), 2014–18
36 Table 12: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the